Immunocore (NASDAQ:IMCR) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of Immunocore (NASDAQ:IMCR) from a hold rating to a buy rating in a research report report published on Saturday.

Several other analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Monday, June 2nd. Deutsche Bank Aktiengesellschaft started coverage on shares of Immunocore in a research note on Tuesday, May 27th. They issued a “buy” rating and a $65.00 price objective for the company. Mizuho decreased their target price on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. JPMorgan Chase & Co. cut their target price on Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, April 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price target on shares of Immunocore in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.89.

Immunocore Stock Performance

Shares of IMCR stock opened at $34.68 on Friday. The stock has a 50-day moving average of $31.06 and a 200-day moving average of $30.29. Immunocore has a one year low of $23.15 and a one year high of $41.54. The stock has a market cap of $1.74 billion, a PE ratio of -36.50 and a beta of 0.83. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to analysts’ expectations of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company’s revenue for the quarter was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.49) EPS. As a group, sell-side analysts expect that Immunocore will post -0.94 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunocore

Hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in shares of Immunocore in the 4th quarter valued at about $25,000. Oppenheimer Asset Management Inc. bought a new position in Immunocore in the 1st quarter worth about $225,000. Checkpoint Capital L.P. purchased a new position in shares of Immunocore during the 1st quarter valued at $267,000. Banque Transatlantique SA bought a new position in shares of Immunocore in the first quarter worth $278,000. Finally, NEOS Investment Management LLC increased its stake in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after acquiring an additional 1,102 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.